AXNX: Axonics, Inc. - Summary | Jitta

Axonics, Inc.

NASDAQ:AXNX

Price
$48.39
Loss Chance
49.6%
4.92JITTA SCORE
720.87%Over Jitta Line
Jitta Ranking
81 / 1,177
1,205 / 5,150
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (74)
Recent Business Performance (86)
Financial Strength (60)
Return to Shareholders (0)
Competitive Advantage (56)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
SG&A to SalesDecreasing Every Year
Revenue and EarningEarning loss detected in 2022
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
4.92
720.87%
1.96
156.71%
Health Care Equipment
5.43
4.79%
5.96
24.26%
4.80
35.25%
COMPANY DESCRIPTION
Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.